Advanced Search

 

Study ID Status Title Patient Level Data
206822 Completed PGx7659: Exploratory Pharmacogenetic Investigation of Efficacy Response to Relvar/Breo in Asthma studies 106827, 106829, 106837, 113091 and 116863
206823 Completed PGx7660: Exploratory Pharmacogenetic Investigation of Efficacy Response to Relvar/Breo in Phase III COPD studies 112206, 112207, 113108, and 200820
207 Completed A bioequivalence study of 50, 100, and 150 mg bupropion sustained-release tablets in healthy male volunteers
207266/084 Completed A Study to Assess the Effect of Repeat Dose NCE on the Steady-State Pharmacokinetics and Pharmacodynamics of Digoxin in Healthy Subjects
207267 Not yet recruiting Assessment of Patients Treated with Albiglutide – Phase 2
207499/039 Completed A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg Twice Daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
207499/040 Completed A Multicentre, Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral SB-207499 (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on ClinicalStudyDataRequest.com
207499/041 Completed A Multicenter Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral Cilomilast (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
207499/042 Completed A Randomized, 24-Week, Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg Twice Daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
207499/076 Completed A 12-week, Multicentre, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Anti-inflammatory Activity of SB207499 15 mg Twice Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD)
207499/091 Completed A Randomized, 24-Week, Double-blind, Placebo-controlled, Parallel-Group Study Followed by a 2-Week, Randomized, Double-blind, Run-out Phase to Evaluate the Efficacy, Safety, Tolerability and Discontinuation of SB207499 (15mg Twice Daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
207499/110 Completed A 12-week, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Anti-inflammatory Activity of Cilomilast 15 mg Twice Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD)
207499/111 Completed A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Effect of Cilomilast (15 mg Twice Daily) on Trapped Gas Volume in Patients With Chronic Obstructive Pulmonary Disease
207499/121 Completed A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of cilomilast (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
207499/125 Completed A Randomized, 12-Week, Double-blind, Placebo-controlled, Parallel-group Pilot Study to Evaluate the Safety and Additional Efficacy of Adding a New Chemical Entity (NCE) to Treatment with ADVAIR 250/50 Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on ClinicalStudyDataRequest.com
207499/156 Completed A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on ClinicalStudyDataRequest.com
207499/157 Completed A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Oral Cilomilast (15 mg bd) When Given as Maintenance Treatment for 12 Months to Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
207499/168 Completed A Randomized, 12-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Tolerability of Cilomilast 15mg Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
207499/180 Completed An 18-week randomized, double-blind, placebo-controlled, multicenter study designed to compare treatment with cilomilast to that with placebo for changes in ventilatory mechanics and function (both at rest and during exercise), as well as related exertional dyspnea and exercise performance, in hyperinflated patients with stable COPD Study Listed on ClinicalStudyDataRequest.com
207499/181 Completed A 13-week randomised, double-blind, parallel group, mulitcentre study to compare the bronchial anti-inflammatory activity of oral cilomilast (15 mg bd) with placebo twice daily in subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
207521 Completed PGx7673: Confirmatory Genetics Reporting and Analysis Plan: Efficacy pharmacogenetic analysis of SLE patients treated with Benlysta in study BEL113750 (eTrack Study ID 207521)
207523 Completed PGx7664: Exploratory PGx evaluation of ALT elevations observed in subjects treated with GSK2881078 (SARM) from study 204699
207697 Not yet recruiting PGx7679: Exploratory Genetic Analysis for GSK2894512 for efficacy in psoriasis patients in 203120
207878 Completed Efficacy and Safety of Belimumab in a Subgroup of Systemic Lupus Erythematosus (SLE) Patients with High Disease Activity (anti-dsDNA positive and low complement and SELENA-SLEDAI score >=10): A Pooled Analysis of the HGS1006-C1056 (BLISS-76) and HGS1006-C1057 (BLISS-52) Studies
207891 Not yet recruiting PGx7682 Exploratory Genetic Analysis for GSK2894512 for efficacy in atopic dermatitis patients in 203121

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.